ViGenCell Inc. Logo

ViGenCell Inc.

Developing T-cell immune therapies to treat cancer and other incurable diseases.

308080 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산로9길 66 더리즌밸리 지식산업센터(가산동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ViGenCell Inc. is a biotechnology company specializing in the research and development of immune cell therapies. The company develops novel treatments for cancers and other incurable diseases, aiming to prolong life expectancy and enhance patient quality of life. Its core technology includes ViTier, a proprietary T-cell therapy platform that employs antigen-specific killer T cells to target and eliminate pathogens or tumor cells. Founded in 2013 as the first subsidiary of the Catholic University Technology Holdings, ViGenCell leverages clinically validated research to advance its therapeutic pipeline.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ViGenCell Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 40.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all ViGenCell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ViGenCell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea 233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875

Talk to a Data Expert

Have a question? We'll get back to you promptly.